Literature DB >> 10030256

Linac radiosurgery for benign meningiomas.

D H Shafron1, W A Friedman, J M Buatti, F J Bova, W M Mendenhall.   

Abstract

PURPOSE: To review outcomes for patients treated with linac radiosurgery for benign meningiomas. METHODS AND MATERIALS: Between January 1989 and July 1997, 70 patients with 76 meningiomas were treated with LINAC-based radiosurgery. In 38 patients, radiosurgery was the initial treatment. In 32 patients, radiosurgery followed surgery or conventional radiotherapy. The average treatment volume was 10.0 cm3 (range, 0.6 to 28.6 cm3). The mean peripheral dose was 12.7 Gy (range, 10 to 20 Gy). The mean clinical follow-up period was 23 months. No patient was lost to follow-up.
RESULTS: No lesions enlarged during the follow-up period; of 48 lesions in patients who had follow-up for at least one year and hence had follow-up imaging, 27 tumors remained unchanged and 21 tumors were reduced in size. Two patients experienced transient radiation-induced neurological deficits. One was treated with surgical excision of the tumor; the other responded to prolonged steroid therapy. Both patients, treated early in our experience, received doses higher than we would currently recommend.
CONCLUSIONS: Early results suggest that stereotactic radiosurgery is an effective treatment for meningiomas. Long-term follow-up will be necessary to fully evaluate its efficacy.

Entities:  

Mesh:

Year:  1999        PMID: 10030256     DOI: 10.1016/s0360-3016(98)00391-5

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

1.  Efficacy of conventional radiotherapy for recurrent meningioma.

Authors:  M Kokubo; Y Shibamoto; J A Takahashi; K Sasai; N Oya; N Hashimoto; M Hiraoka
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

Review 2.  Linac radiosurgery as a tool in neurosurgery.

Authors:  R Deinsberger; J Tidstrand
Journal:  Neurosurg Rev       Date:  2005-02-22       Impact factor: 3.042

3.  Quality of life following surgery for intracranial meningiomas at Brigham and Women's Hospital: a study of 164 patients using a modification of the functional assessment of cancer therapy-brain questionnaire.

Authors:  S N Kalkanis; A Quiñones-Hinojosa; E Buzney; H J Ribaudo; P M Black
Journal:  J Neurooncol       Date:  2000-07       Impact factor: 4.130

4.  Management of benign skull base meningiomas: a review.

Authors:  William M Mendenhall; William A Friedman; Robert J Amdur; Kelly D Foote
Journal:  Skull Base       Date:  2004-02

Review 5.  Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study.

Authors:  Barbara M Hahn; Ulrich M H Schrell; Rolf Sauer; Rudolf Fahlbusch; Oliver Ganslandt; Gerhard G Grabenbauer
Journal:  J Neurooncol       Date:  2005-09       Impact factor: 4.130

Review 6.  Radiotherapy and radiosurgery for benign skull base meningiomas.

Authors:  Giuseppe Minniti; Maurizio Amichetti; Riccardo Maurizi Enrici
Journal:  Radiat Oncol       Date:  2009-10-14       Impact factor: 3.481

7.  Linear accelerator-based radiosurgery in the management of skull base meningiomas.

Authors:  Chi-Cheng Chuang; Chen-Nen Chang; Ngan-Ming Tsang; Kuo-Chen Wei; Chen-Kan Tseng; Joseph Tung-Chien Chang; Ping-Ching Pai
Journal:  J Neurooncol       Date:  2004-01       Impact factor: 4.130

8.  Linear Accelerator-Based Radiosurgery of Grade I Intracranial Meningiomas.

Authors:  Sara Alatriste-Martínez; Sergio Moreno-Jiménez; Guillermo A Gutiérrez-Aceves; José de Jesús Suárez-Campos; Olivia Amanda García-Garduño; Alejandro Rosas-Cabral; Miguel Ángel Celis-López
Journal:  World Neurosurg X       Date:  2019-03-07

Review 9.  Current concepts in stereotactic radiosurgery - a neurosurgical and radiooncological point of view.

Authors:  Jan Vesper; B Bölke; C Wille; P A Gerber; C Matuschek; M Peiper; H J Steiger; W Budach; G Lammering
Journal:  Eur J Med Res       Date:  2009-03-17       Impact factor: 2.175

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.